Filtered By:
Source: Circulation
Condition: Heart Attack
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 272 results found since Jan 2013.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
CONCLUSIONS: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACEs increased across baseline apoB strata. Alirocumab reduced MACEs across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACEs, even after accounting for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of an apoB level ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrom...
Source: Circulation - June 30, 2022 Category: Cardiology Authors: Emil Hagstr öm P Gabriel Steg Michael Szarek Deepak L Bhatt Vera A Bittner Nicolas Danchin Rafael Diaz Shaun G Goodman Robert A Harrington J Wouter Jukema Evangelos Liberopoulos Nikolaus Marx Jennifer McGinniss Garen Manvelian Robert Pordy Michel Scemama Source Type: research
Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology
Circulation. 2022 Apr 19;145(16):1254-1284. doi: 10.1161/CIRCULATIONAHA.121.058229. Epub 2022 Apr 18.ABSTRACTThe Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular microaxial flow pump that is currently used for (1) cardiogenic shock, (2) left ventricular unloading (combination of venoarterial extracorporeal membrane oxygenation and Impella concept), (3) high-risk percutaneous coronary interventions, (4) ablation of ventricular tachycardia, and (5) treatment of right ventricular failure. Impella-assisted forward blood flow increased mean arterial pressure and cardiac output, peripheral tissue pe...
Source: Circulation - April 18, 2022 Category: Cardiology Authors: Enzo L üsebrink Antonia Kellnar Kathrin Krieg Leonhard Binzenh öfer Clemens Scherer Sebastian Zimmer Benedikt Schrage Stephanie Fichtner Tobias Petzold Daniel Braun Sven Peterss Stefan Brunner Christian Hagl Dirk Westermann J örg Hausleiter Steffen Mas Source Type: research
Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study
Conclusions: Over the past 6 decades, mean life expectancy increased and the RLR of ASCVD decreased in the community based, predominantly White Framingham study. The residual burden of ASCVD underscores the importance of continued and effective primary prevention efforts with better screening for risk factors and their effective treatment.PMID:35430874 | DOI:10.1161/CIRCULATIONAHA.121.057889
Source: Circulation - April 18, 2022 Category: Cardiology Authors: Ramachandran S Vasan Danielle M Enserro Vanessa Xanthakis Alexa S Beiser Sudha Seshadri Source Type: research
Deep Lipidomics in Human Plasma - Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation
Conclusions: We identified several lipids associated with cardiometabolic disease risk. A subset was beneficially altered by a dietary fat intervention, which supports substitution of dietary saturated FAs with unsaturated FAs as a potential tool for primary disease prevention.PMID:35422138 | DOI:10.1161/CIRCULATIONAHA.121.056805
Source: Circulation - April 15, 2022 Category: Cardiology Authors: Fabian Eichelmann Laury Sellem Clemens Wittenbecher Susanne J äger Olga Kuxhaus Marcela Prada Rafael Cuadrat Kim G Jackson Julie A Lovegrove Matthias B Schulze Source Type: research
Ablation of Plasma Prekallikrein Decreases LDL Cholesterol by Stabilizing LDL Receptor and Protects against Atherosclerosis
Conclusions: PK regulates circulating cholesterol levels through binding to LDLR and inducing its lysosomal degradation. Ablation of PK stabilizes LDLR, decreases LDL cholesterol and prevents atherosclerotic plaque development. This study suggests that PK is a promising therapeutic target to treat ASCVD.PMID:35189703 | DOI:10.1161/CIRCULATIONAHA.121.056491
Source: Circulation - February 22, 2022 Category: Cardiology Authors: Jin-Kai Wang Yang Li Xiao-Lu Zhao Yuan-Bin Liu Jing Tan Yu-Ying Xing Dilare Adi Yong-Tao Wang Zhen-Yan Fu Yi-Tong Ma Song-Mei Liu Yong Liu Yan Wang Xiong-Jie Shi Xiao-Yi Lu Bao-Liang Song Jie Luo Source Type: research
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Circulation. 2022 Jan 10:CIR0000000000001040. doi: 10.1161/CIR.0000000000001040. Online ahead of print.ABSTRACTCardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to substantial reductions in cardiovascular events. The 2015 American Heart Association and American Diabetes Association scientific statement, "Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence," highlighted the importance of modifying various risk factors resp...
Source: Circulation - January 10, 2022 Category: Cardiology Authors: Joshua J Joseph Prakash Deedwania Tushar Acharya David Aguilar Deepak L Bhatt Deborah A Chyun Katherine E Di Palo Sherita H Golden Laurence S Sperling American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Co Source Type: research
< em > A < /em > ortic < em > V < /em > alve Repl < em > A < /em > cemen < em > T < /em > versus Conservative Treatment in < em > A < /em > symptomatic Seve < em > R < /em > e Aortic Stenosis: The AVATAR Trial
Conclusions: In asymptomatic patients with severe AS, early surgery reduced a primary composite of all-cause death, acute myocardial infarction, stroke or unplanned hospitalization for heart failure compared with conservative treatment. This randomized trial provides preliminary support for early SAVR once AS becomes severe, regardless of symptoms.PMID:34779220 | DOI:10.1161/CIRCULATIONAHA.121.057639
Source: Circulation - November 15, 2021 Category: Cardiology Authors: Marko Banovic Svetozar Putnik Martin Penicka Gheorghe Doros Marek A Deja Radka Kockova Martin Kotrc Sigita Glaveckaite Hrvoje Gasparovic Nikola Pavlovic Lazar Velicki Stefano Salizzoni Wojtek Wojakowski Guy Van Camp Serge D Nikolic Bernard Iung Jozef Bart Source Type: research
